Risk factors of late mortality following liver transplantation

Liver Transplantation: Resection. Therapy and Post-Operative Complications

Volumn , Issue , 2009, Pages 73-101

  Dopazo, Cristina ^a   Bilbao, Itxarone ^a   Escartín, Alfredo ^a   Lázaro, José Luis ^a   Sapisochin, Gonzalo ^a   Caralt, Mireia ^a   Balsells, Joaquín ^a   Charco, Ramon ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895266373     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. National Institute of Health. Consensusdevelopment conference statement: liver transplantation. June 20-23, 1983. Hepatology 1984:4:107S.
2. Adam R, Cailliez V, Majno P et al. Normalised intrinsicmortality risk in liver transplantation; European Liver Transplant Registry Study. The Lancet 2000:v356: 261.
3. American Liver Transplant Registry, OTN/SRTR 2004. Annual Report.
4. Cooper DS, Bellamy P, Dawson NV et al. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997: 113: 1278.
5. Showstack J, Katz P, Lake J et al. Resource utilization in liver transplantation. Effects of patients characteristics and clinical practice. JAMA 1999: 281: 1981.
6. Gilbert JR, Pascual M, Schoenfeld DA, Rubin RH, Delmonico FL, Cosimi AB. Evolving trends in liver transplantation: an outcome and charge analysis. Transplantation 1999: 67: 246.
7. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001: 33: 464.
8. Bilbao I, Charco R, Hidalgo E et al. Risk factors for severe ischemic injury after liver transplantation 1994: 57: 469.
9. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Annals of Internal Medicine 1993; 118: 201-210.
10. NIH Consensus Development Conference Statement. Liver Transplantation. June 2023, 1983. Hepatology 1984; 4 (suppl): 107-109.
11. Rolles K, Williams R, Neuberger J et al. The Cambridge and King's College Hospital experience of liver transplantation 1968-1983. Hepatology 1984; 4 (suppl 1): 50-55.
12. Fonkalsrud EW, Stevens GH, Joseph WL et al. Orthotopic liver allotransplantation using an internal vascular shunt. Surg Gynecol Obstet 1968; 127: 1051-1057.
13. Jain A, Reyes J, Kashycep R et at. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490-500.
14. Busuttil RW, Douglas GT, Hassan Yersiz et al. Analysis of long term outcomes of 3,200 liver transplantations over two decades. A single-center experience. Ann Surg 2005; 241: 905-918.
15. Busuttil RW, Shaked A, Millis JM et al. One thousand liver transplants. The lessons learned. Ann Surg 1994: 219: 490.
16. Bismuth H, Farges O, Castaing D et al. Evaluation des resultats de la transplantation hepatique: experience sur une serie de 1052 transplantations. Presse Med 1995: 24: 1106.
17. Baliga P, Merion R, Turcotte J et al. Preoperative risk factor assessment in liver transplantation. Surgery 1992: 112: 704.
18. Whiting JF, martin J, Zavala E, Hauto D. The influence of clinical variables on hospital cost after orthotopic liver transplantation. Surgery 1999: 125: 217.
19. Gayowski T, Marino IR, Singh N et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998: 65: 499.
20. Clavien PA, Camargo CA, Croxford R et al. Definition and classification of negative of outcomes in solid organ transplantation. Ann Surg 1994: 220: 109.
21. Swartz Sl, Dluhy RG. Corticosteroids: clinical pharmacologic and therapeutic use. Drugs 1978; 16: 238
22. Serrano T, Mitry RM, Terry C et al. The effects of immunosuppressive agents on the function of human hepatocytes in vitro. Cell Transplant. 2006; 15(8-9): 777-83.
23. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. NEJM 1990; 323; 693-699.
24. Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521-530.
25. John M. Rabkin, Christopher L. Corless, Hugo R. Rosen, Ali J Olyaei and Pharm D. Immunosuppression impact on long-term cardiovascular complications. The American Journal of Surgery 2002; 183: 595-599.
26. Thiebaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26: 549.
27. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
28. Lohmann T, List C, Lamesch P, et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108(5): 347-52.
29. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transplant 2001; 7: S22-S26.
30. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving >=5 years after liver transplant. Transplantation 2000; 69: 781-789.
31. McCaughan GW, O'Brien E, Sheil AGR. A follow-up of 53 adult patients alive beyond 2 years following liver transplantation. J Gastroenterol 1993; 8: 569.
32. Cohen AJ, Stegall MD, Rossen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transplant 2002; 8: 916-921.
33. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996; 25: 64.
34. Jindal RM, Sidner RA, Hughes D, et al. Metabolic problems in recipients of liver transplants. Clin Transplant 1996; 10: 213.
35. Stegall MD, Everson G, Schoroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation: diabetes, hypercholesterolaemia, hypertension and obesity. Transplantation 1995; 60: 1057.
36. Krentz AJ, Dousset B, Mayer D, et al. Metabolic effects of cyclosporine A and FK 506 in liver transplant recipients. Diabetes 1993; 42: 1753.
37. Khettry U, Weei-Yuan Huang, Simpson MA, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007; 38 (3): 443-52.
38. McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004; 10 (8): 975-85.
39. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
40. Dane EJ, Portmann BC, Naoumov NV, et al. Long-term outcomeof hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
41. Rosen H, Gretch DR, Oehlke M. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182.
42. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234 (3): 384-394.
43. Charlton M, Ruppert K, Everhart J, et al. Long-term results and modeling to predict outcomes in recipient with HCV infection: results of the NIDDK liver transplantation database. Liver Transplant 2004: 10 (9): 1120-1130.
44. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver Transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplantation registry. Clin Transplant 1998: 17-35.
45. Abbasoglu O, Levy M, Brkie B, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997; 64: 1801-7.
46. Asfar S, Metrakos P, Fryer J, et al. An analysis of late deaths after liver transplantation. Transplantation 1996; 61: 1377-81.
47. Rabkin JM, de la Melena V, Orloff SL, et al. Late mortality after orthotopic liver transplantation. The American Journal of Surgery 2001; 181: 475-479.
48. Vogt DP, Henderson M, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132: 775-780.
49. Neuberger J. Liver transplantation. J Hepatol 2000; 32: 198-207.
50. Sudan DL, Venkataramani A, Lynch J, et al. Causes of late mortality in survivors of liver transplantation. Transplantation 1999; 67; S564.
51. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver transplantation 2001; 9: 811-815.
52. Rosen HR, Medden JP, Martin P. A modelto predict survival following liver retransplantation. Semin Gastrointetinal Dis 1998; 9: 10-25.
53. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66: 1612-16.
54. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-27.
55. Graziedei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-1056.
56. Reich DJ, Fiel I, Guarrera JV, EmreS, Guy SR, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32: 693-700.
57. Fisher NC, Malag M, Gonzalez-Pinto I. The clinical impact of nephrotoxicity in liver transplantation. Transplantation 2000; 69: SS18-22.
58. Munoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis and management. Liver Transpl Surg 1995; 1(supp 1): S29-S38.
59. Reich D, Rothstein K, Manzarbeitia C, et al. Common medical diseases after liver transplantation. Semin Gastrointest Dis 1998; 9: 110-125.
60. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting donor livers: risk factors for poor function after orthotopic liver transplantion. Hepatology 1994; 20: 829-838.
61. Bilbao I, Armadans l, Lazaro JL, Hidalgo E, Castells L, Margarit C. Predictive factors for early mortality following liver transplantation. Clin Transplant 2003; 17: 401-411.
62. Nebbia G, Mattes FM, Cholangitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transplant 2007; 13(1): 130-5.
63. Singh N, Wannstedt C, Keyes L, et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae and mortality) in liver transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79 (10): 1428-34.
64. Ajo AO, Held PJ, Port FK, et al. Chronic renal dysfunction late after transplantation of a non-renal organ. NEJM 2003; 349: 931-940.
65. Nair S, Verma S, Thuluvath PJ. Pre-transplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35 (5): 1179-1185.
66. Moreno JM, Cuervas Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003; 35 (5): 1907-8.
67. Ghobrial RM, Gornbein J, Steadman R, et al. Pre-transplant model to predict post-transplant survival in liver transplant patients. Annals of Surgery 2002; 236 (3): 315-323.
68. Itxarone Bilbao, Cristina Dopazo, Ernest Castro y Carlos Margarit. " Análisis del matching entre donantes y receptores y su impacto en los resultados del trasplante hepático". Medicina Clinica 2006; 7 (5): 18-22. " The impact of donor-recipient matching in the results of liver transplantation". Poster presented in the World Transplant Congress 2006 in Boston 22-26 July 2006.
69. Devlin J, Williams R, Neuhaus P, et al. Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplant recipients. Transpl Int 1994; 7(suppl 1): S522-S526.
70. Canzanello VJ, Textar SC, Taler SJ, et al. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK506). Liver Transpl Surg 1998; 4: 328-334.
71. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7(11): S22-S26.
72. Blanco JJ, Herrero JI, Quiroga J, et al. Liver Transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival and adverse events. Liver Transpl 2001: 7: 226-233.
73. Trail KC, McCashland TM, Larsen JL, et al. Morbidity in patients with post-transplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 276-283.
74. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008 (in press)
75. A Lonardo, P Loria, N Carulli. Dysmetabolic changes associated with HCV: a distinct syndrome. Intern Emerg Med 2008 Publisher Springer Milan. ISSN: 18280447 (Print) 1970-9366 (Online). Category IM-Review. DOI: 10.1007/s11739-0080127-1
76. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: A predictor of diabetes after transplantation. Hepatology 2000; 32: 87-90.
77. Zein NN. Hepatitis C and diabetes mellitus: An ongoing controversy. Am J Gastroenterol 1998; 93: 2320-2322.
78. Mangia A, Schiavone G, Lezzi G, Marmo R, et al. HCV and diabetes mellitus: Evidence for a negative association. Am J Gastroenterol 1998; 93: 2363-2367.
79. Reuben A. Long term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001; 7(11): S13-S21.
80. Abouljoud MS, Levy MF, Klintmalm GB, et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine a US Multicenter trial. US Multicenter Study Group. Transplant Proc. 1995; 27(1): 1121-3
81. Neal D, Glimson A, Gibbs P, et al. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl. 2001;7(6): 533-9.
82. Charco R, Cantarell C, Vargas V, et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg. 1999;5(3): 204-8
83. Charco R, Bilbao I, Chavez R, et al. Low incidence of hypercholesterolaemia among liver transplant patients under tacrolimus monotherapy immunosuppression. Transpl Proc 2002; 34: 1555-1556.